Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Compugen Ltd (Compugen) is a clinical-stage cancer immunotherapy company that develops immunotherapies for cancer. The company pipeline products including COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody targets targeting PVRIG (poliovirus receptor-related immunoglobulin domain-containing protein) which treats Platinum Resistant Ovarian Cancer; COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors; GS-0321, a potential first-in-class, high affinity anti-IL-18 binding protein antibody. Its proprietary Unigen discovery platform combines proprietary AI/ML technology-agnostic cloud-based tools with vast human expertise, enabling the agile discovery of novel drug targets and the continuous development of first-in-class drugs. The company operates in Israel, and the US. Compugen is headquartered in Holon, Sharon, Israel.
Headquarters
Israel
Address
Azrieli Center, 26 Harokmim St., Bldg D, Holon, Sharon (Netanya), 5885849
Website
cgen.com
Telephone
972 3 7658585
No of Employees
53
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CGEN (TLV)
Revenue (2025)
$72.8M
161.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
348.4%
(2025 vs 2024)
Market Cap*
$274.2M
Net Profit Margin (2025)
XYZ
195.1%
(2025 vs 2024)
* As of and is in US$
Compugen Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| COM701: Platinum Resistant Ovarian Cancer |
| COM902: Advanced Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company partnered with Ultima Genomics to combine AI/ML-driven discovery with single-cell sequencing, uncovering new gene insights for immuno-oncology. |
| 2023 | Contracts/Agreements | In December, the company and Gilead Sciences entered into an agreement, under the agreement Gilead Sciences will obtain a license for Compugen's pre-clinical antibody program targeting IL-18 binding protein. |
| 2023 | Corporate Changes/Expansions | In June, Compugen's COM701 (anti-PVRIG) demonstrated its preliminary durable anti-tumor activity in triple immunotherapy with combination of recurrent metastatic MSS endometrial cancer. |
Competitor Comparison
| Key Parameters | Compugen Ltd | AstraZeneca Plc | GSK plc | Simcere Pharmaceutical Group Ltd | BioLineRx Ltd |
|---|---|---|---|---|---|
| Headquarters | Israel | United Kingdom | United Kingdom | China | Israel |
| City | Holon | Cambridge | London | Nanjing | Modi'in-Maccabim-Re'ut |
| State/Province | Sharon (Netanya) | Cambridgeshire | England | Jiangsu | - |
| No. of Employees | 53 | 96,100 | 66,841 | 6,584 | 24 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anat Cohen-Dayag, Ph.D. | Chairman | Executive Board | 2025 | 57 |
| Eran Ophir, Ph.D. | President; Chief Executive Officer; Director | Executive Board | 2025 | - |
| David Silberman | Chief Financial Officer | Senior Management | 2024 | 41 |
| Pierre Ferre, Ph.D. | Chief Operating Officer | Senior Management | 2021 | 48 |
| Michelle Mahler, M.D. | Chief Medical Officer | Senior Management | 2024 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer